Chase Doyle
Authored Items
By Chase Doyle
December 2021 Vol 7 No 6
This article presents recent studies that shed light on racial disparities in the treatment of black and white men who are diagnosed with prostate cancer. Read More ›
By Chase Doyle
July 2021 – Immunotherapy
Immunotherapy is showing good results in patients with advanced skin cancer, one of the most common types of cancer diagnosed in the United States. Read More ›
By Chase Doyle
December 2020 Vol 6 No 6
A chest x-ray and a CT scan revealed a diagnosis of stage IV (advanced) non–small-cell lung cancer after John Doll was experiencing shortness of breath and a lingering cold. Read More ›
By Chase Doyle
November 2020 – Lung Cancer
Frank Sierawski had never smoked and had no family or personal history of lung problems, but what started out as a distressing cough ended up being lung cancer. Read More ›
By Chase Doyle
November 2020 – Lung Cancer
One biomarker that is involved in lung cancer is the ALK mutations. Although several drugs are now available for this type of lung cancer, new evidence shows that some patients may need different therapies. Read More ›
By Chase Doyle
ASCO 2020 Highlights
This article reviews the promising findings presented at the 2020 ASCO meeting showing that treatment with the immunotherapy Libtayo may reduce pain and improve survival without disease progression in patients with advanced cutaneous squamous-cell carcinoma, or skin cancer. Read More ›
By Chase Doyle
ASCO 2020 Highlights
New results presented at the 2020 ASCO annual meeting show that patients with advanced or metastatic (spreading) cutaneous squamous-cell carcinoma (CSCC) who received the PD-1 inhibitor Libtayo (cemiplimab) lived much longer than patients who did not receive this PD-1 inhibitor. Read More ›
By Chase Doyle
ASCO 2020 Highlights
In patients with newly diagnosed multiple myeloma, the use of the 3-drug combination of Kyprolis (carfilzomib), Revlimid (lenalidomide), and dexamethasone for first-line therapy does not improve outcomes compared with the 3-drug combination of Velcade (bortezomib), lenalidomide, and dexamethasone, which is the current standard of care for this patient population. Read More ›
By Chase Doyle
ASCO 2020 Highlights
Cell-based therapy is becoming an attractive option for the treatment of patients with relapsed (coming back) or refractory (does not respond to therapy) multiple myeloma who have received many therapies before. Read More ›
By Chase Doyle
ASCO 2020 Highlights
Zepzelca (lurbinectedin), a recently approved drug for patients with metastatic (spreading) small-cell lung cancer, may be even safer than expected, according to data from 2 studies presented at the 2020 ASCO annual meeting. Read More ›
By Chase Doyle
ASCO 2020 Highlights
Just because a cancer drug is approved by the FDA does not mean its therapeutic benefit is completely understood. Improving outcomes and minimizing side effects of a drug often requires using the drug in different doses or in combination with other drugs. Read More ›
By Chase Doyle
ASCO 2020 Highlights
Induction treatment with endocrine and targeted therapies has significantly improved survival for patients with hormone receptor (HR)-positive advanced breast cancer, but over time almost all patients stop responding to therapy. Read More ›
By Chase Doyle
ASCO 2020 Highlights
New study results presented at the 2020 ASCO annual meeting suggest that there is a new standard of care for the first-line treatment of some patients with advanced colorectal cancer. This was the first study to compare the use of Keytruda (pembrolizumab), a PD-1 inhibitor, versus chemotherapy to see which is the best first treatment for patients with metastatic (spreading) colorectal cancer and microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) abnormalities. Read More ›
By Chase Doyle
ASCO 2020 Highlights
The targeted therapy Calquence (acalabrutinib), a Bruton tyrosine kinase (or BTK) inhibitor, which is approved by the FDA for the treatment of patients with non-Hodgkin lymphoma has now demonstrated long-term remissions as first-line treatment of patients with chronic lymphocytic leukemia (CLL), according to data presented at the 2020 ASCO annual meeting. Read More ›
By Chase Doyle
August 2020 – Immunotherapy
Cutaneous squamous-cell carcinoma (CSCC), or skin cancer, is the second most common cancer in the United States. This article examines the results of a recent study on the first and only immunotherapy approved for patients with advanced or metastatic CSCC. Read More ›
By Chase Doyle
August 2020 – Immunotherapy
A new study was presented at the 2020 ASCO meeting that compared, for the first time, the use of immunotherapy versus chemotherapy for treating patients with metastatic colorectal cancer and microsatellite instability-high or mismatch repair-deficient abnormalities. Read More ›
By Chase Doyle
June 2017 Vol 3 No 3
“It’s important for survivors to talk to their providers about this, even if they’ve had genetic testing a long time ago. The technology has rapidly changed in the past 3 to 10 years,” said Dr. Kapoor of the Encino Breast Care Center. Read More ›
By Chase Doyle
February 2017 Vol 3 No 1
Despite the great advances in cancer therapies, only a small proportion of patients with cancer participate in clinical trials today. This has a detrimental effect on the development of new cancer drugs. Read More ›
By Chase Doyle
June 2016 Vol 2 No 3
In 2002, Diane Heditsian was 48 years old, raising 2 children, running a life science communications firm with her husband of 23 years, and planning a walking tour of Tuscany, when she was first diagnosed with breast cancer. Read More ›